It definitely needed reading twice: Continued strong MABR sales...

It definitely needed reading twice:

• Continued strong MABR sales pipeline in China supports the ramp up of manufacturing capacity to underpin local sales growth
• Our flagship MABR-based products continue to produce a strong sales pipeline in China, and our total backlog now stands at US$278 mill
• This additional credit facility is anticipated to be a corporate loan earmarked for specific projects and, if secured, we view it as an important non-dilutive solution to meet our capital needs as we ramp activity in the back half of this year.
• revenue expectation for our Smart Product Solutions incorporating our MABR technology, AspiralTM and SUBRE, is unchanged and we are ramping up production in China to meet expected demand.
• Given our large pipeline of MABR opportunities (including these provincial opportunities), we are ramping module production to meet demand. We currently have one line installed in our Chinese facility and are moving to full three-shift operations for this one line by year-end.
• Fluence and Generate Capital have executed a term sheet and are in advanced discussion regarding a term loan facility for up to US$40 million with funds earmarked for specific projects, such as the equity portion of San Quintin (outlined above), and the short-term working capital needs in China and Ivory Coast.

Lots to look forward to